Translation of "Méthode de préparation à étapes multiples " (French → English) :

(b) methods and techniques additional to those referred to in Article 13 for the performance of official controls aimed at ensuring the traceability of products falling within the scope of the rules referred to in point (k) of Article 1(2) at all stages of production, preparation and distribution, and at providing assurances as to compliance with those rules.

53. Is convinced that the Code of Conduct on Partnership will strengthen participation within the regions throughout all stages, in form and substance, and must be fully implemented, as it has a fundamental role to play in boosting the effects of cohesion policy and consolidating its impact on the ground; congratulates those Member States and regions that have managed to involve their partners in the preparation of the Partnership Agreements and Operational Programmes in accordance with the Code of Conduct on Partnership; raises ser ...[+++]ious concerns, however, about the numerous cases of weak application of the partnership principle, and calls on the Commission not to approve programmes in which the involvement of partners has not been sufficient; stresses the importance of disseminating examples of good practices in organising partnerships, as detailed in the Code of Conduct; asks, furthermore, the Commission to present, on a regular basis, a report to Parliament assessing the state-of-play of the implementation of the partnership principle;

53. Is convinced that the Code of Conduct on Partnership will strengthen participation within the regions throughout all stages, in form and substance, and must be fully implemented, as it has a fundamental role to play in boosting the effects of cohesion policy and consolidating its impact on the ground; congratulates those Member States and regions that have managed to involve their partners in the preparation of the Partnership Agreements and Operational Programmes in accordance with the Code of Conduct on Partnership; raises ser ...[+++]ious concerns, however, about the numerous cases of weak application of the partnership principle, and calls on the Commission not to approve programmes in which the involvement of partners has not been sufficient; stresses the importance of disseminating examples of good practices in organising partnerships, as detailed in the Code of Conduct; asks, furthermore, the Commission to present, on a regular basis, a report to Parliament assessing the state-of-play of the implementation of the partnership principle;

Mr. Wild: On the point about technical amendments, the government has been preparing motions to address a host of technical issues, mainly drafting errors that arose either because of amendments that occurred during the committee process in the other place, or during report stage, and because of other things that we just missed and did not see.

(Return tabled) Question No. 199 Ms. Kirsty Duncan: With regard to the development and operation of the Canadian Multiple Sclerosis Monitoring System (CMSMS) announced in March 2011: (a) what are the government's baseline assumptions for the CMSMS, (i) how many Canadians live with MS according to the government’s source, (ii) what is the government's source; (b) what have been the challenges in developing the system between March 2011 and today, (i) how has each challenge been overcome, (ii) what are the achievements to date, (iii) what milestones has the government planned between December 2013 and December 2015 and by what dates; (c) ...[+++] what is the cost of developing the system, broken down by costs to date; (d) how much money did the Canadian Institutes for Health Research (CIHR) contribute to the development of the CMSMS, (i) were there any other partners involved in the development of the system, (ii) if so, who are they, (iii) what has each contributed; (e) who was involved in the design and development of the CMSMS, (i) from what departments/institutions were they, (ii) were potential conflicts of interest declared and, if so, how; (f) what health information does the CMSMS track, specifically, with regard to (i) chronic cerebrospinal venous insufficiency (CCSVI), (ii) impacts of CCSVI treatment, including but not limited to use of the following scales, Expanded Disability Status Scale, Modified Fatigue Impact Scale, Multiple Sclerosis Impact Scale, and Multiple Sclerosis Quality of Life Inventory, (iii) pharmaceutical treatments for MS, (vi) adverse drug reactions by MS drug; (g) who is/was overseeing pilot testing, (i) who is/was responsible for ensuring that patient information is/was protected, (ii) who is/was responsible for the integrity of the results; (h) were ethical reviews for pilot testing necessary and, if so, on what date did each pilot site pass ethical review; (i) when is pilot testing expected to/did it take place and at which MS clinics ...

Mr Harbour outlines many of the initiatives and the good points in it and we should be prepared to sell it as a very important step in the services area and as a good day for Europe when this particular directive is adopted.